SIRT联合索拉非尼未显著改善晚期HCC生存
SORAMIC试验姑息队列将不适合TACE的晚期HCC患者按11:10随机分为SIRT联合索拉非尼组与索拉非尼单药组,主要终点为ITT人群总生存。结果显示两组中位OS无显著差异(12.1个月 vs 11.4个月,HR 1.01,95%CI 0.81-1.25,p=0.9529),联合组3-4级不良事件发生率更高。
要点
- SIRT联合索拉非尼较索拉非尼单药未显著改善晚期HCC总生存。
- ITT人群两组中位OS分别为12.1个月和11.4个月,HR 1.01。
- 联合组3-4级不良事件发生率64.8%,高于索拉非尼单药组53.8%。
核心结论
- 在晚期HCC患者中,索拉非尼联合SIRT(90Y树脂微球)较索拉非尼单药未显著改善总生存。
- 亚组分析结果为假设生成性,可支持未来研究设计。
研究设计与样本
- SORAMIC为随机对照试验,包含诊断、局部消融和姑息队列;基于诊断结果将患者分配至局部消融或姑息队列。
- 姑息队列中不适合TACE的患者按11:10随机分为SIRT联合索拉非尼组或索拉非尼单药组。
- 主要终点为ITT人群总生存(Kaplan-Meier分析)。
主要发现
- ITT人群SIRT联合索拉非尼组中位OS 12.1个月 vs 索拉非尼单药组11.4个月(HR 1.01;95%CI 0.81-1.25;p=0.9529)。
- 符合方案人群SIRT联合索拉非尼组(n=114)中位OS 14.0个月 vs 索拉非尼单药组(n=174)11.1个月(HR 0.86;p=0.2515)。
- 符合方案人群亚组分析:无肝硬化患者联合组HR 0.46(0.25-0.86;p=0.02);非酒精性病因肝硬化患者HR 0.63(p=0.012);≤65岁患者HR 0.65(p=0.05)。
- 3-4级不良事件:SIRT联合索拉非尼组103/159(64.8%) vs 索拉非尼单药组106/197(53.8%)(p=0.04);仅接受SIRT组8/24(33.3%)。
关键数值与推荐
- ITT人群主要终点总生存无显著差异:SIRT联合索拉非尼组12.1个月 vs 索拉非尼单药组11.4个月(HR 1.01;95%CI 0.81-1.25;p=0.9529)。
- 符合方案人群总生存:SIRT联合索拉非尼组14.0个月 vs 索拉非尼单药组11.1个月(HR 0.86;p=0.2515)。
- 3-4级不良事件发生率:SIRT联合索拉非尼组64.8% vs 索拉非尼单药组53.8%(p=0.04)。
临床怎么用
- 对于不适合TACE的晚期HCC患者,在索拉非尼基础上加用SIRT(90Y树脂微球)未显示总生存获益。
- 联合治疗组3-4级不良事件发生率更高,临床决策时需权衡毒性。
- 亚组分析结果仅为假设生成性,尚不能直接指导临床筛选获益人群。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma (HCC). We aimed to compare the efficacy and safety of a combination of sorafenib and selective internal radiation therapy (SIRT) - with yttrium-90 (90Y) resin microspheres - to sorafenib alone in patients with advanced HCC. METHODS: SORAMIC is a randomised controlled trial comprising diagnostic, local ablation and palliative cohorts. Based on diagnostic study results, patients were assigned to local ablation or palliative cohorts. In the palliative cohort, patients not eligible for TACE were randomised 11:10 to SIRT plus sorafenib (SIRT + sorafenib) or sorafenib alone. The primary endpoint was overall survival (OS; Kaplan-Meier analysis) in the intention-to-treat (ITT) population. RESULTS: In the ITT cohort, 216 patients were randomised to SIRT + sorafenib and 208 to sorafenib alone. Median OS was 12.1 months in the SIRT + sorafenib arm, and 11.4 months in the sorafenib arm (hazard ratio [HR] 1.01; 95% CI 0.81-1.25; p = 0.9529). Median OS in the per protocol population was 14.0 months in the SIRT + sorafenib arm (n = 114), and 11.1 months in the sorafenib arm (n = 174; HR 0.86; p = 0.2515). Subgroup analyses of the per protocol population indicated a survival benefit of SIRT + sorafenib for patients without cirrhosis (HR 0.46; 0.25-0.86; p = 0.02); cirrhosis of non-alcoholic aetiology (HR 0.63; p = 0.012); or patients ≤65 years old (HR 0.65; p = 0.05). Adverse events (AEs) of Common Terminology Criteria for AE Grades 3-4 were reported in 103/159 (64.8%) patients who received SIRT + sorafenib, 106/197 (53.8%) patients who received sorafenib alone (p = 0.04), and 8/24 (33.3%) patients who only received SIRT. CONCLUSION: Addition of SIRT to sorafenib did not result in a significant improvement in OS compared with sorafenib alone. Subgroup analyses led to hypothesis-generating results that will support the design of future studies. LAY SUMMARY: Sorafenib given orally is the recommended treatment for patients with advanced hepatocellular carcinoma (HCC). In selective internal radiation therapy (SIRT), also known as radioembolisation, microscopic, radioactive resin or glass spheres are introduced into the blood vessels that feed the tumours in the liver. This study found that the addition of SIRT with 90yttrium-loaded resin microspheres to sorafenib treatment in people with advanced HCC did not significantly improve overall survival compared with sorafenib treatment alone. However, the results give an indication of how future studies using this combination therapy in people with advanced HCC could be designed. STUDY REGISTRATION: EudraCT 2009-012576-27, NCT0112 6645.
引用
- Ricke J, Klümpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019. PMID: 31421157. doi:10.1016/j.jhep.2019.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。